CN110520117A - 取代的甘氨酸化合物的共晶及其用途 - Google Patents

取代的甘氨酸化合物的共晶及其用途 Download PDF

Info

Publication number
CN110520117A
CN110520117A CN201880011387.7A CN201880011387A CN110520117A CN 110520117 A CN110520117 A CN 110520117A CN 201880011387 A CN201880011387 A CN 201880011387A CN 110520117 A CN110520117 A CN 110520117A
Authority
CN
China
Prior art keywords
crystal
alkyl
methylglycine
disorder
substituted glycine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880011387.7A
Other languages
English (en)
Chinese (zh)
Inventor
蔡果荃
王景正
谢天岚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SyneuRx International Taiwan Corp
Original Assignee
SyneuRx International Taiwan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SyneuRx International Taiwan Corp filed Critical SyneuRx International Taiwan Corp
Publication of CN110520117A publication Critical patent/CN110520117A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62—Three oxygen atoms, e.g. ascorbic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
CN201880011387.7A 2017-02-13 2018-01-11 取代的甘氨酸化合物的共晶及其用途 Pending CN110520117A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/430,750 US9877942B1 (en) 2017-02-13 2017-02-13 Co-crystals of substituted glycine and uses thereof
US15/430,750 2017-02-13
PCT/CN2018/072186 WO2018145553A1 (en) 2017-02-13 2018-01-11 Co-crystals of substituted glycine compounds and uses thereof

Publications (1)

Publication Number Publication Date
CN110520117A true CN110520117A (zh) 2019-11-29

Family

ID=61005084

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880011387.7A Pending CN110520117A (zh) 2017-02-13 2018-01-11 取代的甘氨酸化合物的共晶及其用途

Country Status (11)

Country Link
US (4) US9877942B1 (enExample)
EP (1) EP3579828B1 (enExample)
JP (2) JP2020507567A (enExample)
KR (1) KR20190118574A (enExample)
CN (1) CN110520117A (enExample)
CA (1) CA3051284A1 (enExample)
IL (1) IL268220B (enExample)
MX (1) MX393880B (enExample)
RU (1) RU2019128576A (enExample)
TW (1) TWI670058B (enExample)
WO (1) WO2018145553A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113233976A (zh) * 2021-05-08 2021-08-10 广州萃普生物科技有限公司 一种没食子酸和氨基乙酸共晶及含有该共晶的美白膏霜

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018015397A (es) * 2016-06-13 2019-08-16 Syneurx Int Taiwan Corp Co-cristales de benzoato de sodio y sus usos.
US9877942B1 (en) 2017-02-13 2018-01-30 Syneurx International (Taiwan) Corp. Co-crystals of substituted glycine and uses thereof
MX2024004855A (es) 2021-10-20 2024-05-06 Purac Biochem Bv Cocristal de acido citrico y glicina y sus usos.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052519A2 (en) * 1998-04-14 1999-10-21 The General Hospital Corporation Methods for treating neuropsychiatric disorders
US20050181041A1 (en) * 2003-12-09 2005-08-18 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
WO2009018368A1 (en) * 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
US20100204204A1 (en) * 2007-06-06 2010-08-12 University Of South Florida Nutraceutical co-crystal compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201411802D0 (en) * 2014-07-02 2014-08-13 Univ Bradford Effervescent compositions
US9877942B1 (en) 2017-02-13 2018-01-30 Syneurx International (Taiwan) Corp. Co-crystals of substituted glycine and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999052519A2 (en) * 1998-04-14 1999-10-21 The General Hospital Corporation Methods for treating neuropsychiatric disorders
US20050181041A1 (en) * 2003-12-09 2005-08-18 Medcrystalforms, Llc Method of preparation of mixed phase co-crystals with active agents
US20100204204A1 (en) * 2007-06-06 2010-08-12 University Of South Florida Nutraceutical co-crystal compositions
WO2009018368A1 (en) * 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
CHON-HAW TSAI MD等: "Activation of N-methyl-D-aspartate receptor glycine site temporally ameliorates neuropsychiatric symptoms of Parkinson's disease with dementia", 《PSYCHIATRY AND CLINICAL NEUROSCIENCES》 *
M.FLECK ET AL.: "Two forms of sarcosine sarcosinium hydrogen L-tartrate", 《JOURNAL OF MOLECULAR STRUCTURE》 *
迟玉杰: "《普通高等教育"十二五"规划教材 食品添加剂》", 30 April 2013, 中国轻工业出版社 *
黄雨婷等: "药物共晶筛选技术的研究进展", 《国际药学研究杂志》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113233976A (zh) * 2021-05-08 2021-08-10 广州萃普生物科技有限公司 一种没食子酸和氨基乙酸共晶及含有该共晶的美白膏霜

Also Published As

Publication number Publication date
IL268220A (en) 2019-09-26
RU2019128576A (ru) 2021-03-15
KR20190118574A (ko) 2019-10-18
MX2019009616A (es) 2019-10-14
JP2020507567A (ja) 2020-03-12
CA3051284A1 (en) 2018-08-16
EP3579828A1 (en) 2019-12-18
US20180228753A1 (en) 2018-08-16
RU2019128576A3 (enExample) 2021-05-14
EP3579828A4 (en) 2020-11-18
US20190262299A1 (en) 2019-08-29
TWI670058B (zh) 2019-09-01
JP2023082101A (ja) 2023-06-13
JP7723991B2 (ja) 2025-08-15
US20180228754A1 (en) 2018-08-16
WO2018145553A1 (en) 2018-08-16
US10328042B2 (en) 2019-06-25
US9877942B1 (en) 2018-01-30
US10765651B2 (en) 2020-09-08
IL268220B (en) 2022-04-01
MX393880B (es) 2025-03-24
TW201840308A (zh) 2018-11-16
EP3579828B1 (en) 2025-03-26
US10328041B2 (en) 2019-06-25

Similar Documents

Publication Publication Date Title
JP7723991B2 (ja) 置換グリシン化合物の共結晶およびそれの使用
US11731928B2 (en) Co-crystals of sodium benzoate and uses thereof
US11739046B2 (en) Co-crystals of lithium benzoate and uses thereof
RU2771810C2 (ru) Сокристаллы бензоата натрия и их применение
HK40017282B (en) Co-crystals of substituted glycine compounds and uses thereof
HK40017282A (en) Co-crystals of substituted glycine compounds and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination